Project Abstract Accelerating Cancer Screening in Matagorda and Wharton Counties MEHOP – H80CS12889 MEHOP has chosen to focus on Colorectal Cancer Screening and Education as well as a focus on Screening for Cancer and Education for Prostate for the (FY) 2022 Accelerating Cancer Screening (AxCS) funding opportunity under the Health Center Program. MEHOP’s collaborative partner is University of Texas MD Anderson Cancer Center ( MD Anderson). MD Anderson is the premier cancer center in the United States. Through a focused effort including education, outreach, screening and care management by dedicated staff for colorectal cancer screening projection for Year End 2023 is 2000 adults 50 to 74 years of age will have had the potential to be screened through the collaboration of MEHOP and MDA. Of 2000 adults, the projection is 1400 will be screened or 70%. Prior to 2022, there has been a lack of focus and ownership by identified staff. MEHOP projects to assist 18 patients with abnormal results within 30 days utilizing our Gastroenterologist. This is based on a 50% increase in number of positives ( 12 is the base) which reflects a 50% increase in number screened ( increase from 225 to 337 screened). Through a focused effort including education, outreach, screening and care management by dedicated staff for prostate cancer screening for prostate cancer screening MEHOP will increase knowledge of screening for prostate to all patients and those community members who attend outreach events for education/screening. The projection for the number of people provided education will be 1200. The projection of increased screening will be 15% of 1200 or 180 patients screened. MEHOP had over 770 patients in our system (including behavioral health, dental, ophthalmology, medical) 55 and over identified as male. Our rate of patients having PSA screening is at 7% for 2021. With the partnership of MDA, MEHOP will assist every patient identified with a positive P
SA within 30 days to determine next steps up to and including a confirmed diagnosis of prostate cancer Through recent success with HPV screening as well as remote patient monitoring, we have proven record of high level of achievement when specific staff are assigned to the specific quality initiatives. MEHOP has included a MOU from University of Texas MD Anderson Cancer Center (MDAnderson). MDAnderson is a NCI-Designated Cancer Center.